View in EDS

Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.

Saved in:
Bibliographic Details
Title: Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.
Authors: Privé BM; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands; Department of Radiation Oncology, Erasmus MC, Rotterdam, Netherlands; Department of Medical Imaging, Radboudumc, Radboud Institute for Health Sciences, 6500 HB Nijmegen, Netherlands. Electronic address: bastiaan.prive@radboudumc.nl., Noordzij W; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands., Peters S; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands., Timmermans BJR; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands., Vrachimis A; Department of Nuclear Medicine, German Oncology Centre, Limassol, Cyprus., Oprea-Lager DE; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands., Nagarajah J; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands; Roentgeninstitut Duesseldorf, Duesseldorf, Germany.
Source: The Lancet. Oncology [Lancet Oncol] 2026 Jul; Vol. 27 (7), pp. e320.
Publication Type: Letter
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42372750
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Privé+BM%22">Privé BM</searchLink>; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands; Department of Radiation Oncology, Erasmus MC, Rotterdam, Netherlands; Department of Medical Imaging, Radboudumc, Radboud Institute for Health Sciences, 6500 HB Nijmegen, Netherlands. Electronic address: bastiaan.prive@radboudumc.nl.<br /><searchLink fieldCode="AU" term="%22Noordzij+W%22">Noordzij W</searchLink>; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Peters+S%22">Peters S</searchLink>; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Timmermans+BJR%22">Timmermans BJR</searchLink>; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Vrachimis+A%22">Vrachimis A</searchLink>; Department of Nuclear Medicine, German Oncology Centre, Limassol, Cyprus.<br /><searchLink fieldCode="AU" term="%22Oprea-Lager+DE%22">Oprea-Lager DE</searchLink>; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Nagarajah+J%22">Nagarajah J</searchLink>; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, Netherlands; Roentgeninstitut Duesseldorf, Duesseldorf, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2026 Jul; Vol. 27 (7), pp. e320.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42372750
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(26)00294-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e320
    Titles:
      – TitleFull: Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Privé BM
      – PersonEntity:
          Name:
            NameFull: Noordzij W
      – PersonEntity:
          Name:
            NameFull: Peters S
      – PersonEntity:
          Name:
            NameFull: Timmermans BJR
      – PersonEntity:
          Name:
            NameFull: Vrachimis A
      – PersonEntity:
          Name:
            NameFull: Oprea-Lager DE
      – PersonEntity:
          Name:
            NameFull: Nagarajah J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2026 Jul
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1